Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.01EUR
151.89 MEUR
2.19 BEUR
186.04 M
About BioMarin Pharmaceutical Inc.
Sector
Industry
CEO
Alexander Hardy
Website
Headquarters
San Rafael
Employees (FY)
3.4 K
Founded
1997
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BM8 is featured.
Frequently Asked Questions
The current price of BM8 is 76.38 EUR — it has decreased by 0.96% in the past 24 hours. Watch BIOMARIN PHARMACEUTICAL INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange BIOMARIN PHARMACEUTICAL INC stocks are traded under the ticker BM8.
BIOMARIN PHARMACEUTICAL INC is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
BM8 stock is 1.02% volatile and has beta coefficient of 0.26. Track BIOMARIN PHARMACEUTICAL INC stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMACEUTICAL INC there?
BM8 earnings for the last quarter are 0.43 EUR per share, whereas the estimation was 0.29 EUR resulting in a 47.52% surprise. The estimated earnings for the next quarter are 0.32 EUR per share. See more details about BIOMARIN PHARMACEUTICAL INC earnings.
BIOMARIN PHARMACEUTICAL INC revenue for the last quarter amounts to 601.30 M EUR despite the estimated figure of 604.10 M EUR. In the next quarter revenue is expected to reach 614.18 M EUR.
Yes, you can track BIOMARIN PHARMACEUTICAL INC financials in yearly and quarterly reports right on TradingView.
BM8 stock has fallen by 0.62% compared to the previous week, the month change is a 4.86% fall, over the last year BIOMARIN PHARMACEUTICAL INC has showed a 12.33% decrease.
BM8 net income for the last quarter is 82.17 M EUR, while the quarter before that showed 18.46 M EUR of net income which accounts for 345.13% change. Track more BIOMARIN PHARMACEUTICAL INC financial stats to get the full picture.
Today BIOMARIN PHARMACEUTICAL INC has the market capitalization of 14.58 B, it has increased by 0.00% over the last week.
No, BM8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BM8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMACEUTICAL INC stock right from TradingView charts — choose your broker and connect to your account.
As of May 8, 2024, the company has 3.40 K employees. See our rating of the largest employees — is BIOMARIN PHARMACEUTICAL INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOMARIN PHARMACEUTICAL INC technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOMARIN PHARMACEUTICAL INC stock shows the strong sell signal. See more of BIOMARIN PHARMACEUTICAL INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOMARIN PHARMACEUTICAL INC future price: according to them, BM8 price has a max estimate of 130.19 EUR and a min estimate of 74.40 EUR. Watch BM8 chart and read a more detailed BIOMARIN PHARMACEUTICAL INC stock forecast: see what analysts think of BIOMARIN PHARMACEUTICAL INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMACEUTICAL INC EBITDA is 300.06 M EUR, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHARMACEUTICAL INC financial statements.